{
    "2018-06-03": [
        [
            {
                "time": "",
                "original_text": "推荐评级 泰格医药(300347)：长期受益于国内创新药产业发展 临床CRO龙头优势突出",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "创新药",
                        "产业发展",
                        "临床CRO",
                        "龙头优势"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}